KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Assets Average (2023 - 2025)

Biocryst Pharmaceuticals' Assets Average history spans 8 years, with the latest figure at $480.3 million for Q4 2025.

  • For Q4 2025, Assets Average fell 2.15% year-over-year to $480.3 million; the TTM value through Dec 2025 reached $480.3 million, down 2.15%, while the annual FY2025 figure was $502.3 million, 0.28% changed from the prior year.
  • Assets Average reached $480.3 million in Q4 2025 per BCRX's latest filing, up from $451.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $526.4 million in Q3 2023 to a low of $324.3 million in Q1 2023.
  • Average Assets Average over 3 years is $476.0 million, with a median of $483.5 million recorded in 2024.
  • The largest YoY upside for Assets Average was 51.82% in 2024 against a maximum downside of 9.55% in 2024.
  • A 3-year view of Assets Average shows it stood at $519.9 million in 2023, then decreased by 5.6% to $490.8 million in 2024, then dropped by 2.15% to $480.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Assets Average are $480.3 million (Q4 2025), $451.8 million (Q3 2025), and $468.6 million (Q2 2025).